VolitionRX Ltd Company Profile (NASDAQ:VNRX)

Analyst Ratings

Consensus Ratings for VolitionRX Ltd (NASDAQ:VNRX) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for VolitionRX Ltd (NASDAQ:VNRX)
Show:
DateFirmActionRatingPrice TargetActions
6/16/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for VolitionRX Ltd (NASDAQ:VNRX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for VolitionRX Ltd (NASDAQ:VNRX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for VolitionRX Ltd (NASDAQ:VNRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for VolitionRX Ltd (NASDAQ:VNRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for VolitionRX Ltd (NASDAQ:VNRX)
DateHeadline
03/14/16 10:20 AMVNRX: Several Key Milestones for 2016 Including European Launch -
03/11/16 06:35 AMVolitionRx Announces Full Year 2015 Financial Results and Business Update - [PR Newswire] - Released interim data from first large-scale clinical trial, a 4,800-subject retrospective colorectal cancer study at Hvidovre Hospital, University of Copenhagen, Denmark. A panel of NuQ® biomarker assays detected 81% of colorectal cancers at 78% specificity equally well for both for early- and late-stage cancers and 67% of high-risk adenomas (polyps most likely to become cancerous). Announced results from first completed prospective clinical trial in colorectal cancer.
03/11/16 05:04 AMVOLITIONRX LTD Files SEC form 10-K, Annual Report -
03/09/16 07:30 AMVolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET - [PR Newswire] - NAMUR, Belgium, March 9 , 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other ...
03/09/16 06:00 AMPreliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease - [PR Newswire] - NAMUR, Belgium, March 9, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced preliminary data from a pilot study demonstrating that the Company's NuQ® blood test detected 86% of subjects with a deadly lung disease, called Idiopathic Pulmonary Fibrosis (IPF). This is the first set of results from a non-cancer trial of VolitionRx's NuQ® blood tests, which demonstrates the technology's potential as a diagnostic for other diseases. The clinical study was conducted with Liège University Hospital in Liège, Belgium.
02/17/16 06:00 AMVolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test - [PR Newswire] - NAMUR, Belgium, Feb. 17, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced results demonstrating that the Company's NuQ® blood test accurately detected 75% of colorectal adenomas, or pre-cancerous polyps, that were most likely to become cancerous. A panel of five of NuQ® biomarker assays also detected 86% of early (stage I) colorectal cancers. The completed clinical trial of 430 patients was conducted with the Hvidovre Hospital and with the University of Copenhagen in Denmark.
02/05/16 12:37 PMVolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer - VolitionRx Limited (NYSE MKT: VNRX) today announced that it has initiated a study to assess the feasibility of using the Company’s NuQ ® blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of ...
02/04/16 12:30 PMVolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection - NAMUR, Belgium, Feb. 4, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today released a video to celebrate World Cancer Day and to offer a message of hope from the inspirational cancer survivor, explorer and campaigner, Sean Swarner. VolitionRx ...
02/04/16 07:00 AM/C O R R E C T I O N -- VolitionRx Ltd/ - [PR Newswire] - In the news release, VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection, issued 04-Feb-2016 by VolitionRx Ltd over PR Newswire, we are advised by the company that the link in the 6th paragraph should read "http://youtu.be/Z7qfaFxGnyY" rather than "https://youtu.be/Z7qfaFxGnyY" as originally issued inadvertently. NAMUR, Belgium, Feb. 4, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today released a video to celebrate World Cancer Day and to offer a message of hope from the inspirational cancer survivor, explorer and campaigner, Sean Swarner.
02/02/16 02:45 PMVNRX: More Positive Trial Data in Colon/Lung Cancers -
02/02/16 06:03 AM7:03 am VolitionRx collaborates with Surrey Cancer Research Institute to initiate prostate cancer study -
02/02/16 06:00 AMVolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK - [PR Newswire] - NAMUR, Belgium, Feb. 2, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced that it has initiated a study to assess the feasibility of using the Company's NuQ® blood tests to detect prostate cancer. In the retrospective study, 550 blood samples collected from patients attending the hospital will be analyzed using a panel of VolitionRx's NuQ® biomarker assays.
02/01/16 06:08 AMCoverage initiated on VolitionRx by Rodman & Renshaw -
01/28/16 06:00 AMVolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests - [PR Newswire] - NAMUR, Belgium, Jan. 28, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), today announced that the Company's subsidiary, Belgian Volition SA, has received the International Standards Organization (ISO) certification EN ISO 13485:2012 for its quality management system for the design, development, production and distribution of its NuQ® blood tests for a broad range of cancers. EN ISO 13485:2012 certification relates to quality management systems in the field of medical devices, including in vitro diagnostic (IVD) devices. The EN prefix denotes that the certification is aligned with the three EU Medical Devices Directives (Medical Devices, In-vitro Diagnostic Devices and Active Implantable Devices).
01/13/16 06:00 AMVolitionRx Releases Annual Shareholder Update Letter - [PR Newswire] - NAMUR, Belgium, Jan. 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today released its annual update letter to its shareholders from CEO Cameron Reynolds. The letter provides a review of the Company's activities and milestones during 2015 and objectives for 2016. In the letter, Mr. Reynolds outlines several key accomplishments over the previous year for the Company, including significant clinical advancements for its NuQ® blood-based testing programs for colorectal, pancreatic and lung cancers, for which test panels in all three indications have demonstrated more than 90% accuracy.
01/06/16 08:00 AMEXCLUSIVE: VolitionRX CEO Talks Trial Updates, Time Until Market -
01/05/16 04:04 PMVOLITIONRX LTD Files SEC form 8-K, Financial Statements and Exhibits -
01/05/16 06:00 AMVolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations - [PR Newswire] - NAMUR, Belgium, Jan. 5, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that Jason Terrell, MD transitioned to full-time status as Chief Medical Officer and Head of U.S. Operations, effective January 1, 2016. Dr. Terrell has served in a part-time capacity as the Company's Chief Medical Officer and Head of U.S. Operations since March 2013. Dr. Terrell will continue to lead and coordinate VolitionRx's U.S. operations in preparation for initial market entry of the Company's NuQ® blood tests for cancer in the U.S. and worldwide.
01/04/16 06:00 AMVolitionRx Granted Its Third U.S. Patent - [PR Newswire] - The new U.S. patent, issued today and expiring in August 2032, relates to VolitionRx's Nucleosomics® platform for the detection of fragments of chromosomes, called nucleosomes, circulating in the blood. Nucleosomes consist of a strand of DNA wrapped around eight protein molecules, called histones.
12/08/15 12:17 PMVOLITIONRX LTD Financials -
12/08/15 06:00 AMVolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study - [PR Newswire] - NAMUR, Belgium, Dec. 8, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced results demonstrating that its NuQ ® blood tests accurately detected 91% of colorectal cancer cases in ...
11/30/15 06:00 AMVolitionRx to Present at LD Micro Conference on December 3 in Los Angeles - [PR Newswire] - NAMUR, Belgium, Nov. 30, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced the Company will present at the LD Micro Conference, which will be held December 1 - 3 in in Los Angeles, CA. Attending from VolitionRx will be David Kratochvil, Chief Financial Officer and Treasurer, and Scott Powell, Vice President of Investor Relations. Kratochvil and Powell will outline VolitionRx's business milestones, plans and commercialization strategy for its NuQ® blood-based tests for colorectal cancer (CRC).
11/24/15 03:05 PMVOLITIONRX LTD Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
11/19/15 06:00 AMVolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy - [PR Newswire] - NAMUR, Belgium, Nov. 19, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced interim data demonstrating its NuQ® blood tests have accurately detected more than 90% of lung cancer cases in a study of 73 patients. The clinical study is part of an ongoing larger prospective study of 240 subjects conducted with the Liege University Hospital (Belgium). The results were the outcome of an interim analysis of the first subjects recruited, including 29 subjects diagnosed with Non-Small Cell Lung Cancer, 22 diagnosed with another pulmonary disease (COPD) and 22 with healthy lungs.
11/17/15 08:00 AMVolitionRx Granted Its Second U.S. Patent - [PR Newswire] - The new U.S. patent, issued today and expiring in December 2032, relates to VolitionRx's Nucleosomics® platform for the detection of changes in fragments of chromosomes, called nucleosomes. Scientists at VolitionRx have discovered that cancer-related proteins that form bonds with chromosomes in living cancer cells can also be detected and measured bound to nucleosomes circulating in the blood of cancer patients.
11/12/15 06:00 AMVolitionRx to Present at Two Conferences in November - [PR Newswire] - NAMUR, Belgium, Nov. 12, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at two conferences in November, the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum in New York and the Biotech Capital Conference in London. During his presentations, Mr. Reynolds will outline VolitionRx's business milestones, plans and commercialization strategy for its NuQ® blood-based tests for colorectal cancer (CRC). Additionally, he will discuss recent clinical developments, including the results from a 4,800-subject cancer trial that demonstrated the Company's NuQ® test accurately detected 95% of pancreatic cancers – the second type of cancer for which VolitionRx currently expects to bring a NuQ® panel test to market, following CRC.
11/10/15 04:20 PMVOLITIONRX LTD Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
11/04/15 05:30 AMVolitionRx Announces Third Quarter 2015 Financial Results and Business Update - [PR Newswire] - NAMUR, Belgium, Nov. 4, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the third quarter ended September 30, 2015. Appointed David Kratochvil as Chief Financial Officer.
11/04/15 05:10 AMVOLITIONRX LTD Files SEC form 10-Q, Quarterly Report -

Social

About VolitionRX Ltd

No company description available

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VNRX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $
  • 200 Day Moving Average: $
  • P/E Ratio:
  • P/E Growth:
  • Market Cap: $
  • Current Year EPS Consensus Estimate: $-0.50 EPS
  • Next Year EPS Consensus Estimate: $-0.44 EPS
Additional Links:
VolitionRX Ltd (NASDAQ:VNRX) Chart for Saturday, July, 23, 2016